You seem to be using an outdated version of Internet Explorer. Please note that this site does not support this browser version (a href="http://windows.microsoft.com/de-de/windows/end-support-help">as does Microsoft). You may experience design inconsistencies and error messages. We are sorry for any inconveniences.

News

High-Tech Gründerfonds, Think.Health Ventures and FLYINGHEALTH invest in M-sense, the certified medical app to combat migraines and headaches

Tackling migraines with a smartphone: The M-sense app launched by Berlin-based start-up Newsenselab GmbH has only been available in the Google Play Store for three months, but it has already documented thousands of migraine and headache attacks and analysed what caused them. The app will soon also offer effective therapy options. Newsenselab GmbH is now the recipient of a six-figure sum in funding as it looks to further expand M-sense and make it available to a broader group of sufferers.

Newsenselab GmbH has attracted investment from two new partners in the shape of financial powerhouses High-Tech Gründerfonds (HTGF) and Think.Health Ventures. Initial investor FLYING HEALTH and an additional private business angel have been supporting the company since the start of the year and are now upping their investment. The product that has impressed the investors goes by the name of M-sense. As a certified medical product, the software analyses the potential trigger factors of migraines and headaches with the help of Big Data. In the future, it will also offer a personalised prevention and therapy programme that is recommended by clinical partners. M-sense is the first app to have been certified as a medical product to combat migraines and headaches. It helps sufferers to document their migraine attacks and analyse their triggers. This represents a major improvement for people suffering from said pain, as specialist treatment will also be possible via their GP. The analysis and recommended therapies are based on the latest medical research data and findings on migraines, as well as the latest medical guidelines.

“We are delighted to have HTGF – a professional and competent partner with experience, an extensive network and a great deal of technological and business know how – at our side in the future,” says Dr. Markus Dahlem, Chief Medical Officer and one of the Berlin-based start-up’s Managing Directors.

“Millions of patients suffer from tension-type headaches and migraines. M-sense has the potential to not only offer guidance to this great number of people, but also to provide therapeutic support, while optimally harnessing the capabilities of medical apps,” adds Dr. Philipp Rittershaus, Investment Manager at High-Tech Gründerfonds.

Following the successful launch of M-sense in early September 2016, the team led by the four Newsenselab GmbH founders has been working on the next stages of the app’s development. By providing sufferers with advice on steps they can take, relaxation techniques and motivation to do strenuous physical exercise, M-sense aims to reduce the frequency of migraine attacks, the intensity of headaches and the amount of medication taken. A biofeedback solution is also planned for a later date. Newsenselab is planning to roll out a similar mobile therapy service for other chronic illnesses as well in future.

M-sense is available in the Google Play Store. An iOS version for iPhones is planned for the first quarter of 2017. You can find more information on M-sense at www.m-sense.de.

About Think.Health Ventures
Think.Health invests in companies in the healthcare and life science sector. Through its active guidance and broad network, portfolio companies receive support and funding as they develop. The Think.Health team has amassed years of expertise in hospital management, healthcare and M&A deals.

Press enquiries:
Dr. Florian Kainzinger
Email: info@think-health.de
think-health.de

About the FLYING HEALTH Incubator
The FLYING HEALTH Incubator provides digital health start-ups with an exclusive environment to ready diagnosis and therapy applications for market entry – with the focus always on the health benefits for patients. It has also amassed a network of partners spanning the entire healthcare system. Buoyed by this ideal form of synergy, the digitalisation of healthcare is being actively shaped in the FLYING HEALTH Incubator.

Founded in 2012, the investment company FLYING HEALTH GmbH serves as the basis for the incubator. Together with this company, founders Dr. Markus Müschenich and Christian Lautner have already been able to enjoy groundbreaking success – the first “app on prescription”, which was launched by the start-up Caterna Vision, as well as the first online video consultation funded by statutory health funds, which was rolled out by the start-up Patientus.

Press enquiries:
Christian Lautner
T: +49 (0)30 2205 602-0
presse@flyinghealth.com
flyinghealth.com

About Newsenselab GmbH
Newsenselab GmbH’s goal is to make chronic diseases that come in the form of reoccurring attacks or phases more manageable for sufferers. In addition to developing software algorithms to detect attacks at an early stage, Newsenselab GmbH also devises mobile therapy options. The start-up receives support from the German Federal Ministry for Economic Affairs and Energy via a programme designed for company founders from the world of science. Newsenselab GmbH was founded as a Berlin-based start-up in January 2016. The company currently has cooperation agreements in place with the following clinical partners: The Charité headache clinic and the neurology centre at the HELIOS clinic in the Buch district of Berlin. The FLYING HEALTH Incubator acts as a healthcare partner.

Images and further information can be found at m-sense.de/press.

Press enquiries:
Juliane Werlitz Newsenselab GmbH
Luisenstrasse 53
10117 Berlin
T: +49 (0) 171 644 01 56
Email: werlitz@m-sense.de
m-sense.de

About High-Tech Gründerfonds
High-Tech Gründerfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gründerfonds invests EUR 600,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Energy, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, Bayer, B. Braun, Robert Bosch, CEWE, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gründerfonds has about EUR 576 million under management in two funds (EUR 272 million HTGF I, EUR 304 million HTGF II).

Contact:
High-Tech Gründerfonds Management GmbH
Dr. Philipp Rittershaus
Schlegelstraße 2
53113 Bonn
T:  +49 228 823 00 – 133
F:  +49 228 823 00 – 050
Email: p.rittershaus@htgf.de
high-tech-gruenderfonds.de